Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Gotlandsbolaget in connection with ship sales
Mandate

Vinge advises Gotlandsbolaget in connection with ship sales

November 30, 2022 Maritime and Transport Law M&A

Gotlandsbolaget and its subsidiary Gotland Tankers have implemented four successful sales of the tankers M/T Gotland Carolina, M/T Gotland Sofia, M/T Gotland Aliya andM/T Gotland Marieann respectively.

The ships are built between 2006 and 2008 in the Gotland Class series. Vinge has advised Gotlandsbolaget throughout the transaction and provided advice in conjunction with contract negotiations, delivery of the ships as well as deregistration from the Bahamian shipping register.

Vinge’s team consisted of Paula Bäckdén and Hanna Marberg supported by  Amelia Rihs  as well as Petronella Hallberg regarding company law issues. The sales mean that all ships of the Gotland Class series have been sold and, according to Gotlandsbolaget, this is part of the company’s strategy to focus even more on industrial shipping and infrastructure.

Related

Vinge advises OsteoCentric on the public offer for Integrum

 OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

 Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

 Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025